Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer? Other Scholarly Work

Passiglia, Francesco, Raez, Luis E, Rolfo, Christian. (2018). Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer? . 10 S1076-S1080. 10.21037/jtd.2018.03.92

Open Access International Collaboration

keywords

  • AFATINIB
  • CHEMOTHERAPY
  • ERLOTINIB
  • GEFITINIB
  • Life Sciences & Biomedicine
  • MULTICENTER
  • MUTATIONS
  • NSCLC
  • OPEN-LABEL
  • PHASE-III
  • Respiratory System
  • SURVIVAL
  • Science & Technology

Digital Object Identifier (DOI)

start page

  • S1076

end page

  • S1080

volume

  • 10